Lv4
500 积分 2022-02-16 加入
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
1个月前
已完结
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
2个月前
已完结
Tunlametinib: First Approval
3个月前
已完结
Neoadjuvant immunotherapy a new standard of care for melanoma
3个月前
已完结
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
3个月前
已完结
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
3个月前
已完结
Top advances of the year: Targeted therapy for lung cancer
3个月前
已完结
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
4个月前
已完结
Cancer incidence and mortality in China, 2022
4个月前
已完结
Targeting KRAS in cancer
4个月前
已完结
皖公网安备34019202002308
